Skip to content

Phase II clinical study for skull base osteoradionecrosis by treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO)

Phase II clinical study for skull base osteoradionecrosis by treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO)

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900024141
Enrollment
Unknown
Registered
2019-06-27
Start date
2019-07-01
Completion date
Unknown
Last updated
2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasopharyngeal carcinoma

Interventions

Case series:PENTOCLO

Sponsors

Jiangxi Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Initial diagnosis of nasopharyngeal cancer patients who have completed radical radiotherapy; Patients with recurrent nasopharynx who have completed two course radical radiotherapy; 2) Nasopharyngeal ulcer found under fiber nasopharyngeal mirror, suspicious recurrence of patients must be biopsy pathology except recurrence; 3) S-B stage is stage II and III, and patients in phase III are recommended for carotid angiography or CTA except for the risk of hemorrhage; 4) Aged 18-70 years; 5) ECOG PS 0-2; 6) Patients sign informed consent form.

Exclusion criteria

Exclusion criteria: 1) Biopsy pathological indications of relapse; 2) Surgical treatment of previously performed nasopharyngeal ulcer(except for diagnostic surgery); 3) carotid arteriography or CTA indication of active hemorrhage or an intracervical aneurysm; 4) History of other malignant neoplasms(except basal cell carcinoma of the skin / squamous carcinoma, cervical carcinoma in situ); 5) Any serious disease that may pose a risk to the test or affect the compliance of the test, such as unstable heart disease, kidney disease, chronic hepatitis, diabetes with poor blood sugar control that requires treatment(fasting blood sugar & GT; 1.5 ULN) and mental illness, etc.. 6) Pregnant or lactating women(women of childbearing age are considering pregnancy tests and patients are required to use effective contraception during treatment).

Design outcomes

Primary

MeasureTime frame
Healing rate;

Countries

China

Contacts

Public ContactTang Yiqiang

Jiangxi Cancer Hospital

johnytangyq@163.com+86 13607916372

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026